News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Interim Report First Quarter 2013

April 18, 2013

PledPharma AB
Interim information

Interim Report First Quarter 2013

First patient treated in the PledOx™ phase IIb study, PLIANT

Stockholm, 2013-04-18 14:00 CEST (GLOBE NEWSWIRE) -- 

Significant events after the end of the period

•    PledPharma proposes a rights issue of shares that can provide the company
with up to 18.6 million SEK. The proposal will be tabled at an EGM to be held
in conjunction with the AGM on April 18. The share issue is done to expand the
PLIANT study with more study centers worldwide to ensure the recruitment rate
and to achieve greater flexibility and time to perform the best possible
out-licensing deal of PledPharma's drug candidate PledOx 


•    All patients included in the ongoing small clinical phase IIa study
MANAMI, examining another PLED-compound’s ability to limit reperfusion injuries
in patients with acute myocardial infarction treated with percutaneous coronary
intervention (PCI) 

Significant events during January – March

•    First patient treated at Uppsala University Hopsital (UAS) in the PledOx™
phase IIb study PLIANT 

•    Green light received from the DSMB (Drug Safety Monitoring Board), an
independent panel of experts) to continue patient recruitment for the phase IIb
study PLIANT 

•    FDA approved the IND application for the clinical trial PLIANT in the US

•    Addition of  the Oncology clinics at Linköping University Hospital and the
University of Texas Health Science Center, San Antonio, USA, to the first part
of the PLIANT study 

•    The Swedish Medicinal Products Agency (MPA) approved expanding the patient
base in the PLIANT study 

•    Patent application regarding the use of PLED compounds in cancer treatment
approved and issued in the US 

•    Net result amounted to SEK -8 032k (-9 277k)

•    Cash and cash equivalents on March 31 amounted to SEK 48 264k (81 646k)

•    Cash flow from operating activities amounted to SEK -10 544k (-8 852k)

•    Result per share amounted to SEK -0.4 (-0.5)



CEO comments

"The first patient is now treated at Uppsala University Hospital (UAS) and we
expect to be able to include the remaining 8-11 patients in the initial
dose-escalation part of the study until mid-2013. Thereafter patients will be
included at all clinics in the subsequent randomized part of the study. 

We have also decided to perform a rights issue of shares as a consequence of
the delay in the recruitment of patients in the first part of the PLIANT study.
We have taken measures to widen the patient base, additional centers in the
first part of the study have been added, and the communication with patients as
well as investigators has been improved. In addition we are offering resources
to facilitate additional test in addition to standard of care to improve
patient acceptance. The additional financial resources will be used to expand
the PLIANT study with more study centers worldwide to ensure the recruitment
rate in the randomized part of the study. With these measures, we believe that
we can get "top line" results from the study by mid-2014. The share issue is
done to achieve greater flexibility and time to implement the best possible
out-licensing deal for PledPharma’s PledOx™, says Jacques Näsström, CEO of
PledPharma. 


For further information please contact:
Jacques Näsström, CEO

 +46 737 130979

Jacques.nasstrom@pledpharma.se



About PledPharma

PledPharma is a Swedish specialty pharma company that develops PledOx™ for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Distmutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit www.pledpharma.se

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com